Previous 10 | Next 10 |
home / stock / bnoef / bnoef news
Investment supports phase IIb clinical trial examining novel PTSD treatment TORONTO, ON / ACCESSWIRE / April 13, 2021 / Novamind Inc. (CSE:NM)(OTC PINK:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, is pleased to a...
Bionomics Successfully Completes A$22.9 million Equity Raise PR Newswire ADELAIDE, Australia , April 9, 2021 /PRNewswire/ -- Bionomics Limited (ASX: BNO, OTCQB:BNOEF) ( Bionomics ) has completed its 1 for 6 pro rata non–renounceable entitlement offer t...
Positive BNC210 7-Day Dosing Pharmacokinetic Study Exceeds Blood Exposure Projected for Phase 2b PTSD Trial PR Newswire BNC210 novel oral tablet formulation (900 mg given twice daily) exceeds blood exposure projected for upcoming Phase 2b PTSD trial BNC21...
Joint feasibility assessment of Bionomics' BNC210 and EmpathBio's MDMA derivative EMP-01 treatment regimen for PTSD PR Newswire ADELAIDE, Australia , Feb. 17, 2021 /PRNewswire/ -- Bionomics Limited (ASX: BNO, OTCQB: BNOEF, Germany : AU000000BNO5) ( Bion...
After several years of turmoil, Bionomics is back on target to finally determine the value of its BNC210 drug for PTSD (Post Traumatic Stress Disorder). Capital restructuring puts the company in good financial position to complete its Phase 2b PTSD trial. Bionomics now has several...
Cedar Clinical Research to be Evaluated to Support Phase IIb Trial of Novel PTSD Treatment TORONTO, ON / ACCESSWIRE / February 11, 2021 / Novamind Inc. (CSE:NM) ("Novamind"), a leading mental health company specialized in psychedelic medicine, is pleased to announce that it has made a...
$16 Million Capital Raise to Progress Bionomics BNC210 PTSD Trial PR Newswire Commitments received for a placement of A$15,991,634 at A$0.145 per share Significant participation from North American and European institutional and sophisticated investor...
Approximately A$20-A$22 million 1 total funding to progress BNC210 development for the treatment of PTSD and other anxiety and stress-related disorders (subject to shareholder and FIRB approvals; exact amount depends upon the take up under entitlement offer) Potential entitlement ...
Bionomics Limited (ASX: BNO, OTCQB:BNOEF), a global, clinical stage biopharmaceutical company, today announced that a paper describing the pharmacology of BNC375, a novel positive allosteric modulator (PAM) of the alpha 7 nicotinic acetylcholine receptor (α7 nAChR), was published onlin...
Bionomics Limited (ASX:BNO, OTCQB:BNOEF), a global, clinical stage biopharmaceutical company leveraging proprietary platform technologies to discover and develop a deep pipeline of novel drug candidates targeting ion channels, is pleased to announce that the Company has accepted an offer from...
News, Short Squeeze, Breakout and More Instantly...
Bionomic Ltd Par Ord Company Name:
BNOEF Stock Symbol:
OTCMKTS Market:
Bionomic Ltd Par Ord Website:
Bionomics Limited Announces Full Exercise of Underwriters' Option to Purchase Additional ADSs in the United States PR Newswire EASTWOOD, Australia , Jan. 5, 2022 /PRNewswire/ -- Bionomics Limited ( Bionomics or Company ), a clinical-stage biopharmaceutica...
Bionomics Limited Announces Pricing of Initial Public Offering in the United States PR Newswire ADELAIDE, Australia , Dec. 16, 2021 /PRNewswire/ -- Bionomics Limited ( Bionomics or Company ), a clinical-stage biopharmaceutical company, today announced the...
U.S. FDA Grants Bionomics Fast Track Designation to BNC210 for the Acute Treatment of Social Anxiety Disorder and Other Anxiety Related Disorders PR Newswire ADELAIDE, Australia , Dec. 1, 2021 /PRNewswire/ -- Bionomics Limited (ASX:BNO, OTCQB:BNOEF) ( Bion...